Sunday, 21 October 2018
Latest news
Main » Jennison Associates LLC Has $59.27 Million Position in Abbott Laboratories (NYSE:ABT)

Jennison Associates LLC Has $59.27 Million Position in Abbott Laboratories (NYSE:ABT)

14 November 2017

Mackenzie Financial Corp decreased its stake in Abbott Labs (ABT) by 96.5% based on its latest 2017Q2 regulatory filing with the SEC. With 394,600 avg volume, 5 days are for Emerge Energy Services LP (NYSE:EMES)'s short sellers to cover EMES's short positions. During the same period in the previous year, the company posted $0.59 EPS. research analysts anticipate that Abbott Laboratories will post 2.5 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, November 15th. It has underperformed by 0.80% the S&P500.

Independent Franchise Partners Llp increased Abbott Labs (ABT) stake by 0.79% reported in 2017Q2 SEC filing. Winfield Associates Inc. boosted its stake in shares of Abbott Laboratories by 3.9% during the second quarter.

Investors sentiment increased to 1.07 in 2017 Q2. Spectranetics Corp now has $1.68B valuation. It is down 15.09% since November 13, 2016 and is uptrending. It has outperformed by 13.19% the S&P500.

The Return on Invested Capital (aka ROIC) for Abbott Laboratories (NYSE:ABT) is 0.168704. Its down 0.75, from 1.63 in 2017Q1. It dropped, as 69 investors sold ABT shares while 545 reduced holdings. 102 funds opened positions while 441 raised stakes.

Abbott Laboratories (NYSE:ABT) traded at an unexpectedly low level on 10/11/2017 when the stock experienced a -1.17% loss to a closing price of $54.8. Eagle Global Advsr Ltd Limited Liability Company stated it has 0.01% of its portfolio in Abbott Laboratories (NYSE:ABT).

Jimmy Kimmel's Famous Friends Roast Him for 50th Birthday Late-Night Spectacular
Though West's Twitter account is now deactivated, you can read reports about the 2013 Twitter feud between West and Kimmel. He then showed a short gag film about Jimmy's life, hosted and narrated by George Clooney .

Ubs Asset Management Americas Inc reports that it bought 180 shares last quarter increasing its holdings in Abbott Laboratories by 1.5%. John G Ullman Associates has invested 2.66% in Abbott Laboratories (NYSE:ABT). (NASDAQ:SYNT) to report earnings on February, 15. Hexavest holds 0.67% or 1.05M shares. Tru Com Of Oklahoma holds 0% or 15,076 shares in its portfolio. Clark Mngmt Gp holds 0.03% or 13,349 shares in its portfolio. Nomura Asset Mgmt Limited reported 37,999 shares stake. Us Fincl Bank De reported 635,794 shares. 810 are owned by Ci Investments Inc.

Cowen and Company updated guidance on ABT with a rating of "Buy" and projecting a price target of $68.00. Therefore 58% are positive. Arcelormittal had 49 analyst reports since July 21, 2015 according to SRatingsIntel.

More notable recent Abbott Laboratories (NYSE:ABT) news were published by: which released: "Abbott Laboratories: Quality Deserves A Price, Just Not This Price" on October 20, 2017, also with their article: "Abbott Laboratories' (ABT) High-Level Sales Growth Make it a Buy" published on November 07, 2017, published: "Abbott Laboratories (ABT) a Buy on Healthy Sales Growth" on October 31, 2017. RBC Capital Markets maintained the stock with "Buy" rating in Monday, October 2 report. On October 19, 2017 Citigroup reiterated a "Neutral" rating on the company. RBC Capital Markets maintained Abbott Laboratories (NYSE:ABT) on Friday, October 9 with "Outperform" rating. For the next financial year, analysts forecast that the firm will post sales of $30.19 billion per share, with estimates ranging from $29.86 billion to $30.59 billion. The rating was maintained by RBC Capital Markets on Thursday, July 23 with "Outperform". Seven analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The analysts, on average, are forecasting a $60.29 price target, but the stock is already up 46.6% from its recent lows. Another trade for 552 shares valued at $26,482 was sold by Watkin Jared.

Miller Howard Investments Inc increased Telephone & Data Sys Inc Com N (NYSE:TDS) stake by 99,061 shares to 215,636 valued at $5.98M in 2017Q2. It also reduced Intuit Inc. Alphabet Inc. Class C was reduced too. Carderock Capital holds 0.21% or 9,725 shares. Therefore 52% are positive. Emerge Energy Services had 36 analyst reports since July 30, 2015 according to SRatingsIntel. The firm has "Buy" rating given on Friday, July 14 by ING Group. Finally, TheStreet upgraded shares of Abbott Laboratories from a "hold" rating to a "buy" rating in a report on Monday, August 22nd. The stock increased 0.91% or $0.5 on November 13, reaching $55.3. SunTrust downgraded the shares of SYNT in report on Monday, October 24 to "Hold" rating. On Friday, September 22 the stock rating was maintained by Stifel Nicolaus with "Buy". The rating was upgraded by TheStreet on Tuesday, August 11 to "Buy". Oppenheimer Asset Management Incorporated, New York-based fund reported 543,684 shares. Oppenheimerfunds, Inc. controls 2,612,696 shares valued at $139,414,000. K.J. Harrison & Partners Inc owns 691,739 shares or 2.07% of their United States portfolio. Louisiana State Employees Retirement System has invested 0.09% in Zoetis Inc (NYSE:ZTS). Its up 0.08, from 0.99 in 2017Q1. 41 funds opened positions while 138 raised stakes. Tiaa Cref Investment Mgmt Limited owns 145,469 shares. Sather Fin Gp owns 5,450 shares for 0.1% of their portfolio. Qs Ltd Liability Com accumulated 25,127 shares or 0.01% of the stock. 8,850 were accumulated by Lmr Prtnrs Limited Liability Partnership. 14,969 are held by Moors & Cabot Inc.

The company now has an insider ownership of 0.5 Percent and Institutional ownership of 73.1 Percent. The Illinois-based Sheffield Asset Management L.L.C. has invested 3.16% in the stock. Company insiders own 0.76% of the company's stock. Commonwealth Of Pennsylvania Pub School Empls Retrmt holds 0.32% of its portfolio in Spectranetics Corp (NASDAQ:SPNC) for 537,585 shares. Finemark Comml Bank & stated it has 3,373 shares or 0.02% of all its holdings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.